A cost-effectiveness analysis of prenatal screening strategies for Down syndrome

Obstetrics and Gynecology

Volumn 106, Issue 3, 2005, Pages 562-568

  Odibo, Anthony O ^a   Stamilio, David M ^b   Nelson, Deborah B ^b   Sehdev, Harish M ^b   Macones, George A ^b  

^a Division of Maternal Fetal Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DOWN SYNDROME; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; MATERNAL SERUM; OUTCOMES RESEARCH; PRENATAL PERIOD; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

EID: 23944521798     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000174581.24338.6f     Document Type: Article

References (30)

1. Mennuti MT, Driscoll DA. Screening for Down's syndrome: too many choices? N Engl J Med 2003;349:1471-3.
2. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.
3. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome on the basis of tests performed in the first and second trimesters. N Engl J Med 1999;341:461-7.
5. Vintzileos AM, Ananth CV, Smulian JC, Day-Salvatore DL, Beazoglou T, Knuppel RA. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or the American approach. Obstet Gynecol 2000;95:577-83.
6. Caughey AB, Kuppermann M, Norton ME, Washington AE. Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis. Am J Obstet Gynecol 2002;187:1239-45.
7. Biggio JR Jr, Morris TC, Owen J, Stringer JS. An outcome analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J Obstet Gynecol 2004; 190:721-9.
8. Kornman EH, Morssink LP, Beekhuis JR, De Wolf BT, Heringa MP, Mantingh A. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996;16:797-805.
9. Economides DL, Whitlow BJ, Kadir R, Lazanakis M, Verdin SM. First-trimester sonographic detection of chromosomal abnormalities in an unselected population. Br J Obstet Gynaecol 1998;105:58-62.
10. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicenter project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;352:343-6.
11. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96:207-13.
12. Brizot ML, Carvalho MH, Liao AW, Reis NS, Armbruster-Moraes E, Zugaib M. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol 2001;8:652-5.
13. Malone FD, D'Alton ME, Society for Maternal-Fetal Medicine. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003;102:1066-79
14. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: A Scottish multicenter study. Br J Obstet Gynaecol 2002;109:667-76.
15. Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13.
16. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56-104.
17. Canick JA, Kellner LH. First trimester serum screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999;23:359-68.
18. Wenstrom KD, Owen J, Chu DC, Boots E. Alpha-fetoprotein, free beta-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1997;177:987-91.
19. Vintzileos AM, Campbell WA, Rodis JF, Guzman ER, Smulian JC, Knuppel RA. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet Gynecol 1996;87: 948-52.
20. Drugan A, Greb A, Johnson MP, Krivchenia EL, Uhlmann WR, Moghissi KS, et al. Determinants of parental decision to abort for chromosomal abnormalities. Prenat Diagn 1990;10: 483-90.
21. Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol. Am J Obstet Gynecol 1993;169:526-30.
22. Lippman A, Tomkins DJ, Shime J, Hamerton JL. Canadian multicentre randomized clinical trial of chorionic villus sampling and amniocentesis. Final report. Prenat Diagn 1992;12: 385-408.
23. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. The Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group. Lancet 1998;351:242-7.
24. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2002. Nat Vital Stat Rep 2003;52:1-114.
25. US Department of Health and Human Services. Medicare. Washington, DC: National Limitations-Clinical Lab; 1995.
26. Harris RA, Washington AE, Nease RF Jr, Kuppermann M. Cost utility of prenatal diagnosis and the risk-based threshold. Lancet 2004;363:276-82.
27. Gilbert RE, Augood C, Gupta R, Ades AE, Logan S, Sculpher M, et al. Screening for Down's syndrome: effects, safety and cost effectiveness of first and second trimester strategies. BMJ 2001;323:423-5.
28. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:102-9.
29. Asch DA, Hershey JC, Pauly MV, Pattton JP, Jedrziewski MK, Mennuti MT. Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis. Am J Public Health 1996;86:684-90.
30. Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment for maternal weight. Br J Obstet Gynaecol 1992;99:144-9.